SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — History and Physical — Franklin D. Roosevelt

PatientFranklin D. Roosevelt
Date of birth1964-01-30
IdentifiersMRN HR-ET002-SYN; SSN (made up) 000-02-5130
Document date2026-03-27
AuthorNathaniel Brooks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for breathlessness, orthopnea, and leg swelling [S]

History of Present Illness

This fictional modern episode addresses the presenting concerns below. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
August 25, 1921Paralytic illness in August 1921, diagnosed at the time as infantile paralysis (polio); paraplegic thereafter, with leg braces from early 1922D (CLM-0003)
Proposed in 2003 about the 1921 illnessGuillain-Barré syndrome proposed retrospectively as the cause of the 1921 paralysis; disputedR (CLM-0004)
May 1941Severe iron deficiency anemia in May 1941, hemoglobin reported at 4.5 g/100 mLD (CLM-0005)

Family History

RelativeConditionAge at deathEvidence
fatherDied in 1900; cause not recorded in the cited sourceD (CLM-0009)
motherDied in September 1941; cause not recorded in the cited sourceD (CLM-0009)

Social History

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2026-03-27 to 2026-04-10completedS
Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route2026-03-27 to 2026-04-10completedS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27 to 2026-06-26completedS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Nicotine 21 mg/24 hr transdermal patch, apply one patch dailyApply one patch to the skin dailyTopical route2026-03-27 to 2026-06-26completedS

Review of Systems

Positive for the concerns in the history of present illness. Alert, fully oriented, and good-humored; tends to minimize symptoms. Mood euthymic; PHQ-2 negative. No other systems reported as affected in this synthetic episode. [S]

General Status

Alert and engaged. Uses a manual wheelchair since a paralytic illness at age 39; independent in transfers and upper-body activities of daily living. Breathless after propelling the wheelchair short distances and when lying flat; NYHA class III at intake. [S]

Physical Exam

Vital signs recorded on 2026-03-27; see the Vital Signs section. Mental status: Alert, fully oriented, and good-humored; tends to minimize symptoms; Mood euthymic; PHQ-2 negative. The physical examination is limited to the findings relevant to this synthetic episode. [S]

Vital Signs

DateMeasureValueUnitProvenance
2026-03-27Body height188cmS
2026-03-27Body weight88kgS
2026-03-27Body mass index (BMI) [Ratio]24.9kg/m2S
2026-03-27Systolic blood pressure186mm[Hg]S
2026-03-27Diastolic blood pressure108mm[Hg]S
2026-03-27Heart rate96/minS
2026-03-27Respiratory rate22/minS
2026-03-27Body temperature36.9CelS
2026-03-27Oxygen saturation in Arterial blood by Pulse oximetry93%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-27Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma2850pg/mL<=125 pg/mLHighS
2026-03-27Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-03-27Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-03-27Creatinine [Mass/volume] in Serum or Plasma1.18mg/dL0.74-1.35 mg/dLNormalS
2026-03-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M70mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-27Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
2026-03-27Hemoglobin [Mass/volume] in Blood12.6g/dL13.2-16.6 g/dLLowS
2026-03-27Ferritin [Mass/volume] in Serum or Plasma48ng/mL30-400 ng/mLNormalS
2026-03-27Iron saturation [Mass Fraction] in Serum or Plasma16%20-50%LowS
2026-03-27Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.45-4.5 mIU/LNormalS
2026-03-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dL<=99 mg/dLHighS
2026-03-27Hemoglobin A1c/Hemoglobin.total in Blood5.9%<=5.6%HighS
2026-03-27Albumin/Creatinine [Mass Ratio] in Urine64mg/g<=30 mg/gHighS
2026-03-27Overall summary score [KCCQ-12]38{score}S
2026-03-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Problems

ProblemClinical statusVerificationCodeProvenance
Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findingsactiveconfirmed I11.0S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D.
Heart failure with reduced ejection fraction, NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic diagnosis confirmed by echocardiogram in the modern episode.
Nicotine dependence, cigarettesactiveconfirmed F17.210S — Synthetic modern diagnosis linked to documented cigarette smoking.
Iron deficiency anemia in heart failure, repleted with intravenous ironresolvedconfirmed D50.9S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S.
Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputedactiveprovisional B91S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R.
Prediabetesactiveconfirmed R73.03S — Synthetic finding from the baseline HbA1c.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.

Assessment

Plan of Treatment